Biopharmaceutical Manufacturing Capacity and Production Trends Eric S. Langer President, BioPlan Associates, Inc. BioPlan Associates, Inc • • • • • Market research and assessments since 1989 New technology evaluation Life sciences ROI models Pricing studies Commercialization Education and Training: – Johns Hopkins and American Universities – Custom programs: Marketing, Management, ROI Why the Annual Studies • Benchmark industry performance • Improve strategic and tactical planning • Identify and quantify trends Bottom-Line Objectives • Provide information that helps: – Reduce production costs – Identify best technologies that reduce costs – Help vendors ensure they are developing products the industry is demanding, sooner. Thinking Forward to 2006 • Your Input will be Invaluable 3rd Annual Report & Survey Methodology • • • • • 187 Biopharmaceutical developers, CMOs 190 suppliers Worldwide assessment Web-based methodology Not intended to identify individual companies, their specific capacity, or utilization • Segments – BioPlan Associates contacts – IBC’s / BioProcess International contacts Report Authors • BioPlan Associates, Inc. – Eric S. Langer, President • Bioprocess Technology Consultants, LLC – James V. Blackwell, PhD, Sr. Consultant – Howard L. Levine, PhD, President – Thomas C. Ransohoff, Sr. Consultant Report Coverage • Demographics • Capacity Utilization • Capacity Constraints / Planned Capacity Expansion • Outsourcing: Critical Issues in Outsourcing • Use of Disposables • Downstream Purification • Training in BioManufacturing • Suppliers to BioManufacturing Demographics Areas of Involvement 0 10 20 Large-Scale Cell Culture Production for Therapeutics 52.9 Large Scale Microbial Fermentation Lg Scale CMO 30 41.7 29.9 Other CMO 27.3 Vaccine Production 25.7 40 50 60 Demographics Biopharmaceutical Systems 0 10 20 30 Mammalian Cell Culture 75.5 Microbial Fermentation Yeast Insect Cells 9.8 Plant Cells 3.3 Other 6.5 40 62 29.9 50 60 70 80 Demographics Phase of Development 0 10 20 30 40 R&D 73.3 Preclinical 75.4 Phase I 62.6 Phase II 63.6 Phase III Marketed 46.5 42.8 50 60 70 80 Capacity Utilization • Percent Capacity, by System • Current Capacity Constraints, Perceptions • Future Capacity Constraints • Factors Creating Capacity Constraints • Plans to Avoid Capacity Constraints • Plans for Capacity Expansion (CMO, Biotherapeutic Developer) Capacity Utilization Average Utilization as % Operating Capacity 0 10 20 30 Mammalian Cell Culture 68.8 Microbial Fermentation Yeast Plant Cells Insect Cells 60.5 44.9 48.1 40.3 40 50 60 70 80 Capacity Constraints “My organization is currently experiencing capacity constraints,” % 2003 - 2005 0 Strongly Agree 10 20 30 40 612.5 21.527 Agree Neutral 25 32 Percent 2003 2005 2128.5 Disagree Strongly Disagree 10.4 10 4 Don't Know 2.1 Capacity Constraints Biotherapeutic Developers vs CMOs • Biotherapeutic developers are 2x as likely to experience significant capacity constraints, compared to CMOs. Factors Creating Capacity Constraints 0 10 20 Lack of Trained Tech/ Production Staff 39.6 Lack of Financing for Expansion 38.9 Physical Capacity of Fermentation Equipment 35.4 Lack of Scientific Staff 30.6 Unable to Optimize System / Quality Control / Unable to Optimize Yield 13 Problems w/ Downstream Purification 12 30 40 50 Key Areas to Avoid Capacity Constraints 0 10 20 Optimize cell culture systems to increase upstream performance 54.2 Improve downstream purification performance 43.8 Streamline FDA regulatory process 38.9 Fund more early-stage scale-up production technologies 36.1 Increase training in production areas 35.4 Develop cost-effective disposable/ single-use technologies 30 24.3 40 50 60 Future Capacity Expansion Projected Avg % Increase Production Capacity by 2010 0% 10% 20% Mammalian Cell Culture 54% Microbial Fermentation 40% Yeast 30% Plant Cells 28% Insect Cells 30% 14% 40% 50% 60% Future Capacity Expansion % Projecting > 100% Increase in Capacity by 2010 0% 5% Mammalian Cell Culture 12% Yeast 12% Insect Cells 15% 28% Microbial Fermentation Plant Cells 10% 11% 8% 20% 25% 30% Outsourcing By Production System Outsourcing in 2010 Critical Issues in Outsourcing Outsourcing by 2010 % Planning to Outsource SOME Production, by 2010 0% 10% 20% 30% Mammalian Cell Culture 62% Microbial Fermentation 61% 58% Yeast 67% Plant Cells Insect Cells 40% 40% 50% 60% 70% 80% Critical Outsourcing Issues 0 20 CMO must establish a good working relationship 40 52.8 CMO has production platforms relevant to my product 50 CMO is able to stick to a schedule 47.2 CMO demonstrates track record with products similar to mine 47.2 CMO demonstrates cost effectiveness (ROI) of their Services 37.7 60 Use of Disposables • Types used • Percentage used • Reasons for increased use (CMOs & Biotherapeutic Developers) • Factors restricting use • Current spending Factors Restricting Use of Disposables 0 0 .1 0 .2 0 .3 Leachables and Extractables 69% Breakage of Bags/ Loss of Product 58% Don’t want to be dependent on 1 Vendor 57% Already invested in current system 55% Current disposables systems don’t meet my requirements 54% No lifetime operating cost data exists Can’t change for regulatory reasons 50% 34% 0 .4 0 .5 0 .6 0 .7 0 .8 Downstream Purification • Where are Improvements Needed? • Magnitude of Problems Associated with Microfiltration Training in Biopharmaceutical Manufacturing • Types of Training • Percent biomanufacturing workforce trained in past 12 months • Internal vs External Training Types • Training by Facility Size Suppliers to BioManufacturing & Life Sciences • Biomanufacturing Market Growth • What Suppliers Must Demonstrate to Customers What’s Next for 2006 • • • • • Downstream Purification Disposables HTP Assays and Data Management Optimization of Yield and Performance Training in Production Areas What’s Next for 2006 • Your Input is Invaluable